0000064803-14-000040.txt : 20141216 0000064803-14-000040.hdr.sgml : 20141216 20141216073311 ACCESSION NUMBER: 0000064803-14-000040 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20141216 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20141216 DATE AS OF CHANGE: 20141216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01011 FILM NUMBER: 141288316 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 8-K 1 form8-k2014analystday.htm 8-K Form 8-K 2014 Analyst Day




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934


Date of Report (Date of earliest event reported): December 16, 2014


CVS HEALTH CORPORATION
(Exact Name of Registrant
as Specified in Charter)
 
 
 
 
Delaware
001-01011
05-0494040
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
One CVS Drive, Woonsocket, Rhode Island 02895
(Address of Principal Executive Offices)
 
Registrant’s telephone number, including area code: (401) 765-1500
 
N/A
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))










Item 2.02                   Results of Operations and Financial Condition.
 
On December 16, 2014, CVS Health Corporation (the "Company") issued a press release announcing that it has reaffirmed its earnings guidance for 2014 and provided 2015 guidance. Attached to this Current Report on Form 8-K as Exhibit 99.1 is a copy of the Company's related press release dated December 16, 2014.
 
The information in this report is being furnished, not filed. Accordingly, the information in this report will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.
 
Item 9.01                   Financial Statements and Exhibits.
 
(d)                           Exhibits
 
99.1                  Press Release, dated December 16, 2014, of CVS Health Corporation.
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
CVS HEALTH CORPORATION
 
 
 
 
By:
/s/ David M. Denton
 
 
David M. Denton
 
 
Executive Vice President and
 
 
Chief Financial Officer
 
 
 
 
 
Dated: December 16, 2014



 EX-99.1 2 pressreleasedateddecember1.htm PRESS RELEASE Press Release, dated December 16, 2014
        



Exhibit 99.1

CVS Health Provides 2015 Guidance and Outlines Plans for Sustainable Enterprise Growth at Annual Analyst Day

Announces 27% Dividend Increase and
New $10 Billion Share Repurchase Authorization

Highlights of 2015 Guidance:
•
Adjusted EPS expected to be in the range of $5.05 to $5.19, up 12.5% to 15.75% (excluding the loss on early extinguishment of debt in 2014)
•
GAAP diluted EPS from continuing operations expected to be in the range of $4.77 to $4.91
•
Free cash flow expected to be between $5.9 billion and $6.2 billion
•
Cash from operations expected to be between $7.6 billion and $7.9 billion
•
Expect to complete approximately $6 billion in share repurchases

 WOONSOCKET, R.I., December 16, 2014 – Declaring that it is positioned for today and preparing for tomorrow, CVS Health (NYSE: CVS) outlined the steps the company is taking to continue to meet the changing needs of payors, providers and customers at its annual Analyst Day in New York City today. The company also provided 2015 guidance and reviewed its 5-year steady state targets, highlighting how CVS Health plans to thrive while creating value for all of its stakeholders.

“We are winning in the marketplace and driving solid and sustainable growth,” said Larry Merlo, president and chief executive officer of CVS Health. “We foresaw the changes ahead in the health care landscape and we built a suite of assets that will enable us to continue to capitalize on the opportunities created. Only CVS Health has an integrated enterprise model that brings differentiated, channel-agnostic solutions to the marketplace that our competitors simply cannot match. Our deep clinical expertise and insights across the enterprise enable us to deliver superior outcomes at a lower cost.”

At the meeting, Dave Denton, executive vice president and chief financial officer, reaffirmed the company’s guidance for 2014 and outlined CVS Health’s guidance for 2015. The company expects to deliver adjusted earnings per share from continuing operations of $5.05 to $5.19 in 2015, an increase of 12.5% to 15.75% (excluding the loss on early extinguishment of debt in 2014), and GAAP diluted earnings per share from continuing operations of $4.77 to $4.91 per share. The company also expects to generate substantial free cash flow of $5.9 billion to $6.2 billion in 2015, and cash from operations of $7.6 billion to $7.9 billion in 2015. This guidance assumes the completion of $6 billion in share repurchases during 2015.



Page 1 of 1



“We’ve established a solid track record of delivering on our promises, and our results prove that out. Looking ahead, we are targeting solid, long-term enterprise growth and expect to generate a significant amount of cash that will be available to enhance returns,” said Denton. “Some of that cash will be used to invest in the business, such as through strategic, bolt-on acquisitions that drive continued share gains. The rest will be returned to our shareholders through dividends and value-enhancing share repurchases.”

CVS Health highlighted its position as a pharmacy innovation company that utilizes a channel-agnostic, enterprise focus to fulfill its purpose of helping people on their path to better health while driving value for all stakeholders. In other presentations, CVS Health executives addressed how the company is preparing for the continued evolution of the health care delivery system through its pharmacy benefit management operations and unique specialty pharmacy assets as well as how the company is reinventing retail pharmacy, expanding access to care through CVS/minuteclinic and helping to create a more connected health care system to improve outcomes for patients while better managing costs for payors.

Merlo addressed how health reform has changed the payor landscape as millions of Americans have gained insurance coverage. Health reform is also driving the importance that health plans are playing in the health care marketplace now and into the future. CVS Health sees this as an opportunity to grow its enterprise share by continuing to serve these health plans through its innovative offerings, either as PBM clients or as strategic partners when the plans are not PBM clients.

In another growing trend, as specialty drug utilization is increasing and new treatments for complex conditions are coming to market at elevated price points, plan sponsors can expect to see specialty drug costs grow to nearly half of their total pharmacy spend.

“With rapid specialty pharmacy growth expected for the next several years,” said Merlo, “plan sponsors will clearly need innovative solutions to stem the tide. We believe we are best-positioned, with an unmatched suite of specialty capabilities to holistically manage patients and help payors manage this spend in both the pharmacy and medical benefit.”

Merlo predicted that the “retailization” of health care will continue to grow as more employers move their employees into consumer-directed health plans.

“We will be able to win in a connected health care system with our consumer-friendly offerings such as the convenience of CVS/pharmacy and the low-cost, transparent pricing model of CVS/minuteclinic. Both of these are trusted brands with name recognition to attract value-conscious consumers,” said Merlo. “We are also expanding our digital offerings to better engage with customers, improve their experience and increase medication adherence. With the growing focus on population health, there has been a desire among physicians to increase communication and coordination with their patients’ pharmacists and that is an area where we can excel.”

Page 2 of 2    12 16 14 CVS Health Outlines Plans for Sustainable Enterprise Growth



Dividend Increase and New Share Repurchase Authorization
The company also announced that its board of directors approved a 27% increase in its quarterly cash dividend, to $0.35 per share on the common stock of the company. This increase translates to $1.40 per share annually, up 30 cents per share, and keeps the company solidly on track to meet its 2018 dividend payout ratio target of 35%. The quarterly dividend is payable on February 2, 2015, to holders of record on January 22, 2015.

In addition, the company announced that its board of directors approved a new share repurchase program for up to $10 billion of the company’s outstanding common stock, reflecting the board’s ongoing commitment to returning value to shareholders. The share repurchase authorization, which is effective immediately and is expected to be completed over a multi-year period, permits the company to effect the repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase transactions, and/or other derivative transactions. Combined with approximately $2.7 billion that remains on the share repurchase program approved by the board of directors in December of 2013, this new $10 billion share repurchase authorization makes available a total of approximately $12.7 billion for share repurchases.
 
Webcast
The company will simultaneously broadcast an audio and video webcast of the meeting for all interested parties through the Investor Relations section of the CVS Health website at http://cvshealth.com/investors. This webcast and supporting materials will be archived and available on the website for a one-year period following the meeting.

About CVS Health
CVS Health is a pharmacy innovation company helping people on their path to better health.  Through our 7,800 retail pharmacies, more than 900 walk-in medical clinics, a leading pharmacy benefits manager with nearly 65 million plan members, and expanding specialty pharmacy services, we enable people, businesses and communities to manage health in more affordable, effective ways.  This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs.  Find more information about how CVS Health is shaping the future of health at www.cvshealth.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. By their nature, all forward-looking statements involve risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking statements for a number of reasons as described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2013 and under the section entitled “Cautionary Statement Concerning Forward-looking Statements” in our most recently filed Quarterly Report on Form 10-Q.

12 16 14 CVS Health Outlines Plans for Sustainable Enterprise Growth    Page 3 of 3



Non-GAAP Financial Measures
This press release contains certain non-GAAP financial measures, namely Free Cash Flow and Adjusted Earnings Per Share or “Adjusted EPS.” In accordance with SEC regulations, you can find the definitions of the non-GAAP items mentioned, as well as the reconciliations to comparable GAAP measures, on the Investor Relations section of our website at http://cvshealth.com/investors.



Contacts:
Nancy Christal
Investor Relations
914.722.4704
 
Carolyn Castel
Corporate Communications
401.770.5717


Page 4 of 4    12 16 14 CVS Health Outlines Plans for Sustainable Enterprise Growth
 GRAPHIC 3 cvshealthlogo.jpg begin 644 cvshealthlogo.jpg M_]C_X0RI17AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!```` M8@$;``4````!````:@$H``,````!``(```$Q``(````@````<@$R``(````4 M````DH=I``0````!````J````-0`"OR````G$``*_(```"<0061O8F4@4&AO M=&]S:&]P($-3-B`H36%C:6YT;W-H*0`R,#$T.C`Y.C`R(#$W.C`V.C(V```` M``.@`0`#`````0`!``"@`@`$`````0```/J@`P`$`````0```#$````````` M!@$#``,````!``8```$:``4````!```!(@$;``4````!```!*@$H``,````! M``(```(!``0````!```!,@("``0````!```+;P````````!(`````0```$@` M```!_]C_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$``P("`@) M"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P, M#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$, M#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`!\`H`,! M(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@) M"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@% M`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A M\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7% MU>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34! M``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:B MLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F M=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`.]Z_P#6KI/0/3;F M.>^ZW5E%(#K-O'JN#G5M97N_??[_`/!_GJPSK_2']*/5QDM&"!+K3V/^C+/I M^KN]OI?37CWU@IZK3UC)'5Y.:YY<]YX<#]!]7_`[1^B_<9^C5'UK?2]#>[T2 M[>:Y.W6_Z5@8ZQKZ]WM^E[/\)_@UH=0ZE@],QCE9]S:* M6F-SNY/YK&ME]C_Y#%XGT6OJEG5,=O2=PSMTTN9R#^E/^,[ZNBW8*\HMF/4%;=L?O?SOJ?\`@:TLCZY]`HPJ<_UW M6XM[G5MMK8YP:]H#C5=INIMVG>QEGTV>]9&%]0.B9'U=I'ID9]^.VP99>Z1: M]OJ#V-=Z?I,<[9L]/^;_`.%_2+)?]0.I]/Z/U/UKZ;F&D7,96'%PMH=ZC7MW M-;_VG=ET?]?1XLX%D`V+T_18O8^%SEPQGDQF,QC,9G^=C\O%'YGO.D=8P>L8 MGVO!>7TAQ82X%I#F\C:[^LLVCZ[]`R,X8%-MEEY>:QMK<6^V=]F_Z/HL:WU' MV?Z/WKC?J3]8/V9T;K59?#J:OM.,V)_2']6G_MUV(J'U5Z'F=1P^K9&*`;:< M8U4@S)?:?TC:S^\_%KOH_P#0A#WY$0X0"9`F7^"O_P!%882YDY92CCQ2A#%* M^N7]_3]'C@]ME_XR?JWC7&JOU\H#0V4L&R?(W/IW?V5J=$^L_1^N!S<&T^LQ MNY]%@VV!L[=VWZ+V_P#%N>O)^C=1PNEY%[>I=,9GAP]-U=Q+'UD'W[9:_:_] M[]'ZG_"5KJ_J71]3[NL5W].OS,?/J#G5XV0ZO:\%KFVLK-=9]38QW^D]7_"? MF(8\TY2%F.IUCL5W.?#.7Q8IF,,OHCQ1S>G)CG_?C'Y(O15?7CHMO5AT=K,K M[;O],L./9`EWI"Y[MOMQ]W^'_FU=Z]]8^G=`H9D=0%WHO)!?54^QK8C6UU8+ M:OI?GKE,WJXZ5_C,S+W8F7FA_3*V"K"I-[Q^D:[>]C2-M?M^DH?77ZVLSOJM MU'$'2.K8QMK`];(Q'5U-][#^EM+O8U6G#>TZ1U?%ZQAC-Q&VMI<2&^M6ZIQT M#M[66ANZM[7>QZO+EKOK%9TKHW1,#!Q_MO5^IX];,+&)VL]E3'W9&1;^930T M[W?GV?\`@E=?.Z[]>.@4?M+KF)T_-Z966C+_`&<;FWU-<=KL@,R_9=77^XW_ M`,#J]2U)3V*2YKK7UIR6YF)T?ZN45Y_5,ZH9+;+"X8U.,3#E= M39_.,_2?SB2GILGZS=,Q>M4=$O%S,O*,4.-3_2>=OJ.V7QZ;]C?I[5K+A^MG MJ7_.+ZF_M44C.]?+]88I>:9V,V>EZP;;_-[?IK/H/UM_\RZ;]9NF=2ZGD]*H%S,S#&ZVNZIU?MW>F'M]0#?9&3UNO\`QD]4HZ)CTW9EV%1^ERGN;12QNUS[+FU`W6[W;*:JJ?\` M2>I_-UO6STWZP=?Q>O4="^LN/C-NSV66=/R\$V>D\U#?=CV5Y&ZQEK*OTN_^ M;24__]#OOK']6\+K^'Z-_P"COKDX^0!+F./_`%=3O\)6O*7_`%8ZRSK/[%-! M.63+8^@6?]R&V?Z#^7_UO^=_1KVU0_1>J/H^KM,<;MLZ_P`K;N463!&9!V/7 MQ=#DOBF;E8R@/7`@\$9?Y.?[P_J_U'(^K/U7P_J_B[61;EV`?:,@C4_R&?N5 M-7,?XR?J[E775]9Q*S:QM?IY36"2W9N>S8^9^\D\FQ_H[?= MI=2RKN^?Z3.7CP?NOAW7<%_2.L9W3FDLK8\M#0[FIQ;D4-?^][/1?\`\8O0 M_J]TOJ6!]1P>E$5]3RF_:V%T.#BXM>ROW^S])B,97[O\*NM.WO"=*&`1D3>X M(']6T\S\6GGQ8\9Q@<$HSF2>..:4/WH5\LGR8?7*]UMU/UDZ;3U)X&P-M8VF MVIPG>W?Z3K&JO]4NFY'4_K+1D8-!IQ<;(&1802YE5;7>JRCU7>Y[G;?1K_PC M_P#MQ>I]0_8N]O[2^R[X]GVCTYC^3ZRM8_V?T6?9MGH1[/3C9'\C9[4WV"2# M*7$`;V]7^,R'XMCCCG'#@]J>2/`?6?9C_6AB^1X+"^L71'?XT[)%S&_9Q[?I^U:G^,[J.%B_5+,QYKJWO:V/W6KJ1Z& M[3;NGRF5)_IZ;X\IC^*L.0^7]3=T[)9]7/K(V_(MZ1B8QZ=U/(P76,?C.],! MMSG4;+_2]2S;D_R/]+ZM=2N9[?J0ZAN-C=4ZAUF_.'IU=.Q,ZV]]H=])EM?J M>E56UGZ2W[5Z?Z-B]$9LCV1'EPJF!^Q_4M_9WV;U)_3?9]FZ?^%]+_OZ2GC[ MQC_4[ZV8G4DO'47%U5F7?1^DJHKWM-;[VK#ZGTFMF#D M'Z%KGVUN8VMX]ON:U=O9]F]!WJ[/0CW;HV1_*W>U*S[-MK]79MW-]+=$;_\` M!^GN_/\`W-J2GA^E=;Z2_P#QG]3:W*83?CUXM0U]UU1_34C3Z;/3>E];^O=& MQOKS]7!D9==7[-.6 M8E)3_]G_[13T4&AO=&]S:&]P(#,N,``X0DE-!`0```````\<`5H``QLE1QP" M```"````.$))300E```````0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@`````` M_P```!`````!```````+<')I;G1/=71P=70````%`````%!S=%-B;V]L`0`` M``!);G1E96YU;0````!);G1E`````$-L#A"24T$&0``````!````!XX0DE-`_,````` M``D```````````$`.$))32<0```````*``$``````````3A"24T#]0`````` M2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@```````0`R`````0!: M````!@```````0`U`````0`M````!@```````3A"24T#^```````<```____ M_________________________P/H`````/__________________________ M__\#Z`````#_____________________________`^@`````____________ M_________________P/H```X0DE-!`````````(``3A"24T$`@``````!``` M```X0DE-!#````````(!`3A"24T$+0``````!@`!`````SA"24T$"``````` M$`````$```)````"0``````X0DE-!!X```````0`````.$))300:``````-1 M````!@``````````````,0```/H````.`$,`5@!3`$@`90!A`&P`=`!H`%\` M;`!O`&<`;P````$``````````````````````````0``````````````^@`` M`#$``````````````````````0`````````````````````````0`````0`` M`````&YU;&P````"````!F)O=6YD'1) MD%L:6=N M96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L=`````EV97)T06QI M9VYE;G5M````#T53;&EC959E7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90````!.;VYE````"71O M<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG``````````QB;W1T M;VU/=71S971L;VYG``````````MR:6=H=$]U='-E=&QO;F<``````#A"24T$ M*```````#`````(_\````````#A"24T$%```````!`````0X0DE-!`P````` M"XL````!````H````!\```'@```Z(```"V\`&``!_]C_[0`,061O8F5?0TT` M`?_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3 M$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+ M#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#/_``!$(`!\`H`,!(@`"$0$#$0'_W0`$``K_Q`$_ M```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!```````` M``$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B M<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V M%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G M=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1 M%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1E MXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>G MM\?_V@`,`P$``A$#$0`_`.]Z_P#6KI/0/3;F.>^ZW5E%(#K-O'JN#G5M97N_ M??[_`/!_GJPSK_2']*/5QDM&"!+K3V/^C+/I^KN]OI?37CWU@IZK3UC)'5Y. M:YY<]YX<#]!]7_`[1^B_<9^C5'UK?2]#>[T2[>:Y.W6_ MZ5@8ZQKZ]WM^E[/\)_@UH=0ZE@],QCE9]S:*6F-SNY/YK&ME]C_Y#%XGT6OJ MEG5,=O2=PSMTTN9R#^E/^,[ZNBW8 M*\HMF/4%;=L?O?SOJ?\`@:TLCZY]`HPJ<_UW6XM[G5MMK8YP:]H#C5=INIMV MG>QEGTV>]9&%]0.B9'U=I'ID9]^.VP99>Z1:]OJ#V-=Z?I,<[9L]/^;_`.%_ M2+)?]0.I]/Z/U/UKZ;F&D7,96'%PMH=ZC7MW-;_VG=ET?]?1XLX%D`V+T_18 MO8^%SEPQGDQF,QC,9G^=C\O%'YGO.D=8P>L8GVO!>7TAQ82X%I#F\C:[^LLV MCZ[]`R,X8%-MEEY>:QMK<6^V=]F_Z/HL:WU'V?Z/WKC?J3]8/V9T;K59?#J: MOM.,V)_2']6G_MUV(J'U5Z'F=1P^K9&*`;:<8U4@S)?:?TC:S^\_%KOH_P#0 MA#WY$0X0"9`F7^"O_P!%882YDY92CCQ2A#%*^N7]_3]'C@]ME_XR?JWC7&JO MU\H#0V4L&R?(W/IW?V5J=$^L_1^N!S<&T^LQNY]%@VV!L[=VWZ+V_P#%N>O) M^C=1PNEY%[>I=,9GAP]-U=Q+'UD'W[9:_:_][]'ZG_"5KJ_J71]3[NL5W].O MS,?/J#G5XV0ZO:\%KFVLK-=9]38QW^D]7_"?F(8\TY2%F.IUCL5W.?#.7Q8I MF,,OHCQ1S>G)CG_?C'Y(O15?7CHMO5AT=K,K[;O],L./9`EWI"Y[MOMQ]W^' M_FU=Z]]8^G=`H9D=0%WHO)!?54^QK8C6UU8+:OI?GKE,WJXZ5_C,S+W8F7FA M_3*V"K"I-[Q^D:[>]C2-M?M^DH?77ZVLSOJMU'$'2.K8QMK`];(Q'5U-][#^ MEM+O8U6G#>TZ1U?%ZQAC-Q&VMI<2&^M6ZIQT#M[66ANZM[7>QZO+EKOK%9TK MHW1,#!Q_MO5^IX];,+&)VL]E3'W9&1;^930T[W?GV?\`@E=?.Z[]>.@4?M+K MF)T_-Z966C+_`&<;FWU-<=KL@,R_9=77^XW_`,#J]2U)3V*2YKK7UIR6YF)T M?ZN45Y_5,ZH9+;+"X8U.,3#E=39_.,_2?SB2GILGZS=,Q>M4= M$O%S,O*,4.-3_2>=OJ.V7QZ;]C?I[5K+A^MGJ7_.+ZF_M44C.]?+]88I>:9V M,V>EZP;;_-[?IK/H/UM_\RZ; M]9NF=2ZGD]*H%S,S#&ZVNZIU?MW>F'M]0#?9&3UNO\`QD]4HZ)C MTW9EV%1^ERGN;12QNUS[+FU`W6[W;*:JJ?\`2>I_-UO6STWZP=?Q>O4="^LN M/C-NSV66=/R\$V>D\U#?=CV5Y&ZQEK*OTN_^;24__]#OOK']6\+K^'Z-_P"C MOKDX^0!+F./_`%=3O\)6O*7_`%8ZRSK/[%-!.63+8^@6?]R&V?Z#^7_UO^=_ M1KVU0_1>J/H^KM,<;MLZ_P`K;N463!&9!V/7Q=#DOBF;E8R@/7`@\$9?Y.?[ MP_J_U'(^K/U7P_J_B[61;EV`?:,@C4_R&?N5-7,?XR?J[E775]9Q*S:QM?IY M36"2W9N>S8^9^\D\FQ_H[?=I=2 MRKN^?Z3.7CP?NOAW7<%_ M2.L9W3FDLK8\M#0[FIQ;D4-?^][/1?\`\8O0_J]TOJ6!]1P>E$5]3RF_:V%T M.#BXM>ROW^S])B,97[O\*NM.WO"=*&`1D3>X(']6T\S\6GGQ8\9Q@<$HSF2> M..:4/WH5\LGR8?7*]UMU/UDZ;3U)X&P-M8VFVIPG>W?Z3K&JO]4NFY'4_K+1 MD8-!IQ<;(&1802YE5;7>JRCU7>Y[G;?1K_PC_P#MQ>I]0_8N]O[2^R[X]GVC MTYC^3ZRM8_V?T6?9MGH1[/3C9'\C9[4WV"2#*7$`;V]7^,R'XMCCCG'#@]J> M2/`?6?9C_6AB^1X+"^L71'?XT[)%S&_9Q[?I^U:G^,[J. M%B_5+,QYKJWO:V/W6KJ1Z&[3;NGRF5)_IZ;X\IC^*L.0^7 M]3=T[)9]7/K(V_(MZ1B8QZ=U/(P76,?C.],!MSG4;+_2]2S;D_R/]+ZM=2N9 M[?J0ZAN-C=4ZAUF_.'IU=.Q,ZV]]H=])EM?J>E56UGZ2W[5Z?Z-B]$9LCV1' MEPJF!^Q_4M_9WV;U)_3?9]FZ?^%]+_OZ2GC[QC_4[ZV8G4DO'47%U5F7?1 M^DJHKWM-;[VK#ZGTFMF#D'Z%KGVUN8VMX]ON:U=O9]F]! MWJ[/0CW;HV1_*W>U*S[-MK]79MW-]+=$;_\`!^GN_/\`W-J2GA^E=;Z2_P#Q MG]3:W*83?CUXM0U]UU1_34C3Z;/3>E];^O=&QOKS]7!D9==7[-.68E)3_]D`.$))300A``````!5 M`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!! M`&0`;P!B`&4`(`!0`&@`;P!T`&\`&UL M;G,Z&UL;G,Z M>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN7!E+U)E7!E+U)E&UL;G,Z<&AO=&]S:&]P/2)H='1P M.B\O;G,N861O8F4N8V]M+W!H;W1O&UP34TZ1&5R:79E9$9R;VT@&UP+FEI M9#I&.$8U0C&UP+F1I9#HP,C@P,3$W-#`W,C`V.#$Q.#`X,S@U-C8W-#)% M,C@Q1"(@#IX;7!M971A/B`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(#P_>'!A8VME="!E;F0](G0``9&5S8P`````````2D!\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B M`JP"M@+!`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8# MH@.N`[H#QP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$ M!-,$X03P!/X%#044%]@8&!A8& M)P8W!D@&609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L M![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60) M>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI M"X`+F`NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X- MJ0W##=X-^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`) M$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2 MPQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6; M%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8 MU1CZ&2`911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ M'%(<>QRC',P<]1T>'4<=:AZ4'KX>Z1\3'SX?:1^4'[\? MZB`5($$@;""8(,0@\"$<(4@A=2&A(B>K)]PH M#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN M+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<-]1B)&9T:K1O!' M-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU* M39--W$XE3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3 M]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF M6O5;15N56^5<-5R&7-9=)UUX7&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A M]6))8IQB\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E# M:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q M.G&5&YXS'DJ M>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N! MS8(P@I*"](-7@[J$'82`A..%1X6KA@Z&I+CDTV3 MMI0@E(J4])5?EAMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF M_:=NI^"H4JC$J3>IJ:H_R#W(O,DZR;G*.,JWRS;+MLPUS+7--:6YQ_GJ>@RZ+SI M1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q'EZA8:'B(F* ME)66EYB9FJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V M]_CY^A$``@$#`@0$`P4$!`0&!@5M`0(#$00A$@4Q!@`B$T%1!S)A%'$(0H$C MD152H6(6,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B M\E5E=58WA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G M=X>7I[?'U^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK* MVNKZ_]H`#`,!``(1`Q$`/P#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>] M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^ MZ]U[W[KW7O?NO=>]^Z]U[W[KW7__T+9OYUW\[F+H]-U?$7X@[G2?NETJ<%VY MW#@ZI)(.HEHX^"O+WDVLKR0"LNW[=*M#N%, MI4P78>,GKE&Z,7ET+"1IG^YAD*ST\T-3'%,F/VR1[KD#F_EJW?93%H@:*... M6S8"B2V;A?T)(S2@4:&6L:VO\I>S,+6 M8[>B;BH?O<)\>YH=5#E,IA\I54L6-W]G,HY,NWWCB--!`PJT?]V'O%A[O;K)[K[G! M=^U&USJ]L87TR[N#W)')&K%[2*,46[!;6S@Q6S,C?4)JO]5_+/Y&],]V47R( MV%W!OJ@[?I\T,YD=XY#<64S5?NFH>?SUU%O3^*U54N[\1E]3)64N0\\-3&[! MU-[B"+#F#>=MW-=XM-QE&XAM1H>I.L'S#5!ZZP\V>T/MKSMR-/[<$ELD,<20`"B-;>&J_3R1X,HQ=3(*6J+%J>HJLO^ M1>>K#G*QJ-,6[Q*/%BK^6M*Y,9/YJ>UO(M\Y'WK/NI\V?=JYK"2&2_\`;N^D M;Z#<-/'BWTMUI&F.[C4$TPDZ`RQ`4DCB`+^<]_-L'\O;9NW^LNHJ3#;A^3G: M.'JLQ@ES40KL'UALI:FHQ@W]G<5K3^,9/)Y.FGIL+0N132STE1/4ZHJ<4U64 M^Y7N#_5"VAL=O57WR=25U96)*T\1AYDD$(O`D$M@:6D+[DOW0#]XO>MQYIYQ MFGMO:W:IECE\(Z);ZYTA_I(I*'PT1&1[F4=ZK)''%1Y#+#HF=K_)#Y3_`"RW MB:GM?MGMONO=6X*UEH<%DLYG<]3M4S%I!C]L;*QS?P7$4H()CH\;0P0)SHC' M/O%>_P!ZW[F"YU7^X7%S.YPI9FSZ*@[0/DJ@?+KOERC[9^T_M#LPBY1Y0V?8 M]IMX^Z5(HHCI&-<]R_ZLC>LDTK,?-CTP[:W]\C_B_NZ&7:F[>Y>@M[T!@KTB MQ.7WEUKGXXW8M#-/1PS8>KEI*@HP*R(T4RZE(87'MJ"[WG8[@&WN+FTNAG!> M-OV8-#\\'HPW3E_VT]U-G=-VV?9.8=BDJA,D=M>PDCB`Q$BAEKQ4AE-"*&G5 M\F`_FI?(SYU_`_N[H7>79V\=F_+CX[;>IOD7U7VYU=N3,=9YSN7KKK-98NWM MG[S79%9A(JC<>V>M\QD_W(ON!LO*UE>^SW M,ERVSW^WWT,=[%MMY>T.WW%M]4LI$,]['#:G63)`T^A)&CG$<=470?\`,7^6 MG5O>'4'9&Y?DS\AMV[9V+V7LC=6YMJY_N3L?/X3RV%R>XZJ M@R=!FL1!-32PR1LKI*?S8^P%M/.7,%CNFW7L^]WDD$4Z.R--(RLJL"RE2Q!# M"H(/KUEQ[@_=L]H.:^1.';;.*6":6%TBFCE2%71X MI"KJRD$%?3KZ:V_.SMI]>]4[R[ES.0ADV/LGK[*3$T;2(U])!!^GO-N[OK>SL+G:98%1AQ!$C`$<>OEX[P^?OS2WCN[=.[IOE M1\B;W'+B<'W=V;C,+BYR&R[/M. MSI[3601(J!Y':`L\C:=3NQ+,Q)))/5HGS$_F?_+GX^]4= M7?`+K7N3LG;>Z>KNO<#/\G.Y:W=V?ROZ.P:%.P=Z;#HNPLQ75FZ-M[:Z MKJ]T+MY6HIJ6MFJ,;*GE%*B1N.>8^>>8=HL+'E*RW*9)X(5^IF+L9GFD'B/& M)"2RK$6\/M(8E2*Z:`XJ^S'W5_9WW$YNYJ^\+S/R5MESM.Z[C*-DVU;>*/;; M;;;1S:6UTUG&JP33WZP&\(E62)4F5M!E+,M4NQ/CE\T?E3C<_P!G=>=/?(?O M[&8?(S4V>WUM_:>_.Q8H\W#!#75-!)GH*7*/6YR&EJHII*>.22J2.5'90'4D M!6NS7:*U&=4DD[N)&JAJU"#2I.1Z]9;;_`.Y7LC[37.W\KX>N,Q'0U'AR&"S^Q,W6&EQE21&].]31K0Y2DN MWAGB<7]K=CYRYFY9ND>QW&4(C4:&0LT9IQ5D8T'I4:6'D1T&/=3[M?LA[X[% M<6W-')E@]S<1:H=PM(XH;R,N*I+%=1+J<9#A)#+!)C7&XZWSL])!_.,_E@TD MG3W>'9_Q,KODAMK95>O:G4F7K:?LWJ+='7?:FWLUOO;."R^*S&UJZ43YO860 MV]/.E32?=XNLDD*:)?$V9O+>^6_,FR;?O5LNF.=*E>.E@2KK7STL"*XJ`#3/ M7S0>]/M;N_LM[HV>]3":[VNZT)*!I$\$B+-;SA:G3XL$D;E*MH8LFHE2> MM,3^4Y\2_F!\M_YIGSJ^*F[?YL/SRQ&U?Y=G>6YL;BLJ>Y.S]P#N3'=3?(K/ M=<"@W=@/CVUC\YY:6.1Z5&\*QV1>1[KW6_%\'_`(U[C^(/QKJ_)=B[Y.Z-_;JWI32;CK_=>Z][]U[KWOW7NO>_=>Z][]U[K7*_X4A_&3M7?/PWWO\`+[JG MYF_)CXQYWX:]/=G[P@V+T1O[<>Q=N=OUV-:V;3IU&_NO=#7_PFT[([$[<_DL?#'L+M??N].SM_;@_V8K^/;X["W3G- MZ;PS?\)^5_>N$Q?\7W-N2NR6:R7\-PN-IJ.G\T[^&EIXXDM&BJ/=>Z%_^6E_ M-YZ=_F<=F_,SJ_J[J_LOKS*_"O?>U-A;WR._I=K28_=N0W;N#MW;U'6[5&W< MSE:E*.EJ>GZV23[M('T54.D$ZPONO=:RO_"L;J7Y)?$3)8KY\=+_`,P3YC[) MC^2'=>Q^K&^.^RNX]^;$ZBZWQ^U>@VHJC*[/H=J;NQRQ5FXLEUK_`!&L0T\: M25N3J9#J:IV/LRIJ9I:BHJ-J;=GGGGD>6:>:7$4[?AY\A=]]1=[8W)#<\6 M7R6P<#E9"RY2BW"5=YCJ,]-6":GJ%CJ(I8UP+YF MV'<^7-XN]OW5&\?46#GA*I)I(I\PWGY@U!H01U]:?L=[L\C>\WMSL'./(-U% M^ZS"D4ENM`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`)8: M.JGPB2DLB:@&/567Q7_X397'NA[>\R\C+[,C;[F^CC\*Z7=C M,UM/!-'<6]PL1VV/6T,\4ALO\7_DMW?\?\T*AZGJGL?< MNU*&LJE"S9?;M+7R3[3W`5"H!'N/:]11UZ>E?14#@?3WCIO^U2;'O>Z;1+75 M;S,@)\U![&_VRT;\^NSGM%[@6?NI[8S.WR"3_'+A4M#ZUC)#U_TT41K_IQZ M]0\&^O5"@?\`*,P&%)ZU MZ_Y3OQH_V:[Y]_'CK"OQ_P#$-GXW>$/9/8DQ=*VZR>))Z:(^\@_)B`GVL.NC'WNO<__ M`%H_N]^X_-5O<>'O,MD;*S(-&^JO?\7C=/Z4"N]S_I86X\.AD_GA?&?L3X^_ MS".\]Q;HPN139/?&\8X;<>/W;)#E=Q8RBKB#!_%-H;DKIZ&JI2 MPFAC6"8H(:B!G,O=#9+S:.;]TFGB;Z6[D,T;^3!\L`?5&)4CB,'@14%_<3]T M.6_<3[NG(6V[5>Q'?.7[*/;KVW!'B0O;@QPNR<=%Q"J2QR4TL3(E2\<@5E^! M/\Y#Y:?R^]HS]8]:P]=[[ZEJ]QUVZ)=@]C;=K*J/'Y;+14<&8K,!N3;>6V[N M+'2Y"*@B/CGGK**.53(M.&>0NURG[C\P7+>'(I-":5*LI5A6@ MP25KFF35;]X'[EOM#]XG>(^:>9WW*PYO2V6`7=G,JEXXRQC66&:.:%PA=NY% MCD*D*9**NFU;IO\`FT?RA^^-_5F6^97\MKK/K/>V_,_59;=W;N)V9M3N';V2 MW'FZQZS,[KW?&VV]M[YHER%9/)/.U+1YRJ:1R6UW9P/=M]P/;S=;MI.9.2X( M+F5R7E"),I9C4N_:KBIR:!S7K$SG3[H/WQ>0.7X;3V5^\UNFZ;'M]NL=OM\E MS/MTR0Q*%C@MSXTUJVA0%0/):H%%!2@'6W;\=]H=`[-ZCVE2_&'!]>8'I3.4 MC;MV7#U73XJGV+D:+#&!I`/```8Z^=W\&OYJG0O\JS^=W_`#O^P.^NNN_NQ<1VK\J_D[L[ M`4706R=K;VS&.R6&^7'96:J:K<%+NG?NPH*'&RTSZ(I(IJAVEX**/5[,^@-U M?C_T&$_RY_\`O&#^8_\`^B#ZB_\`NB_?NO=4)?-#^:=T/_-1_GH_R3>Q^ANN M^^^NL+U=\D?C5LC.T'?FRMK[)S60RF2^56S\]!5X&CVOOS?E/6XN.DF"/)+- M`XE!4(1ZO?NO=;C_`/.I_FV;0_E+?&?#]@4VTX>T_D)W'N&JZ^^.'4$DU7%3 M;KW=3TM//E]R[C&-/\7DV5LF+(TC5L5#:LKJRNHJ&)X#5_=4_NO=4^]??RY? M^%*?S*VOC^\?DU_-SE^#NZMW4D.XMO\`QUZ5Z[-1#U_CLA$*J@VOO2/9&:ZW MQN/RU`CA)H9FS/D ME\8?DKE8MN](?-G;6)H<)7[=K9Y*2/R>M<[L;Y2=&;@HZK;^-JZS;F\^MZ[;^+W!M MK>-"_GFQF*P5203#58^%HXZFN]U[K8?^:O4WS?Z8_P"$^G\Q+9W\P'Y)[4^5 M7?3=6=HY>+M'9NT<3LG#IL:NCVG%MW;)PV%V?LBC-7B:NEK)'F^RUR"H4&1M M("^Z]T77^3]U1\VNY?\`A-'\'-F_`+Y(;5^+'?IWOWIE4[2WCM+$[UPZ[+H? ME]\EEW'MTX7-;0WO1?=9>2>F9)?LMNWN^OYH M>'^"?SYZV^,>_>O^WNNL9\H-T;NZQVSO&C[JW?7;S^2=+MW/X"BS'5V\X=O4 MV)S."W)4/%3P8Y9%S$2E&$2K%[KW5U__``M1AR%-_+P^'M/EJI*[*0?*[%0Y M*MC18HZS(1=']F)654<:I$L:5%0K.%"J`#:P^GOW7NE5U!\4_P#A0U_,\ZEV M)\G]V_S(<7_+0ZP[#VC@]T="?&GI;8V4S&X<#UID,533[(KNS-P8O*;'S\F= MW-@VIZZ85N5RTRK4!FH\ZG_!W^9!_,I_E\?S-]@?RDOYON^]L?(# M`_(:@H9/BM\L\)CZ+'UN4R&:FRU!LS%Y?(T."VW4;EQF[=R86?`3T^4HFS^) MW#+!JJZK&3PS^_=>ZW%??NO=?__2W$?GW\`ND_Y@_2];U=VI0)B]RXI*W(=7 M]I8VBIY]U]:[GGA1!D,:\C0MDL!DF@BCRN*DE2GR$"+ZHJB*FJ8`MS;REMG- M^VM8WZ:9UJ8I0.^-O4>JG&I":,/0A6$\_=[^\+SS]W7G>#FOE.X,NURE4OK% MV(M[V`$]C@5T2I5C!<*I>%R\-O_`,-S>/O7 M[=W'CQ45&T]_;6FGEBQN[MGY6:"#^(X>N\3*ZLJ5%)4))3U$<4\;QKAES%RY MN?*^YR[9ND.F495A\$B^3H?,']H-00"".OI@]F?>?D;WVY(V_GKD3="36XDJ M'@IY9(]O_;Z\YPNQ!2"L8(/A0U#W#B@TQB21/H<]6]6]>])]?;3 MZJZIVEA]C=>['Q$&$VOM;!4_V^/Q>/@+.0"[25%765=1(\]353O+4U=3))-- M))+([MF!86%GMEG;V%A;K%9Q+I55X`?Y2>))J222222>OG'YKYKYCYYYBW?F MWFW>)K_F._F,L\\IJ[N?V!54`*B*%2-%5$5455'SG/YY'2V;Z8_F8?(I= MMYUJ1'.PF0^HD`)(^QPZ_:.OI.^X?SO8\[?=?]MC;3JU[M,,FVW"`U,_ML=:9'=?84';G6&9WGF*#;V MWMS93+;9P>T-W;87/96:DQ='GH*?:&*FHJ:657KEEF$0+Q:6D#V6YKVS;X-Q MY?W*[2!Y)O%B+D*K$JJ.NHT`;L0J">ZIID=8?_WG'L!SSSCNW)GN]R7R]=;I M;6FW';[Z.VC>::"..>6XMY_"C#.T1-Q.LKJI$15"]%>HMC_FX?S@-D_"WI_$ M4'QS[%ZB[%^2>[-SXB#%;2%?2;_QNV=F4XGK-Q;GW?C]L9^B?%PU,<,5%CTG MJH)JF>I,D4>)A(5):28JC*B M(%=D:2,-5!_+W_GF_P`PSY??,KH/X]9?;_1$FV-_[T1-[2[>ZZW+1Y>CV)M_ M&Y#<^\JRAKZC?E?38^JAV[AJCQ320R(LI7TL2%(`Y0]TN<.8N9-IV>2&T\": M7OTQL"$4%G(/B$`Z0:$@YZRY^\7]PS[N7LW[*^X/N-9[COXW7;['_%A->0M& MUU,Z06RL@M$9U,TB:E5@2M<@5(!W_A3Y\:/[C_)7J7Y/87'^+"]Z['EV=N^I M@ANA["ZK%'24M=7SJ`$GS.PLQC::G1N63"RD$A2%+O?'9/I=ZV_?(D_2NHM# MG_AD5`"?]-&5`_TAZ&G]UC[G_O[VQYO]K+ZXK>[!?BYMU)_XAW^IF5!YB.[C MF=R.!N4!XBNNSD^Z-]9;I'9WQ_J\D6ZZV1V5OWM7#XT&0N=T]@[ND-KR1L%GSUO7N)#;4YDOMLM+"1\4\"TFNYXP,5U,]VPD))U+%",:.MM'_A M+7\:/L=M_(;YQYX"XU34>2R=5M^%)$L M@FQTZ$L00N0'L5LFF#>.894RY$$9^0H\GY$F,?:I'7(3^];]S_'W/VX]GK&X M_3MXWW6[4&H\237;68-.#(BW;$'.F9&P"*F0^7/\\[^6/E]Q=I?%_P"4/Q2^ M07:$?6^_]V;#W5MW=/471VY:R6VV\J>ZGM5[M\N[4VY[=;W<$T&X;I#*8+F-)TCF$6V,C`JRB6)FDC+` MJ=0'16NH/Y5?\G[^9[U;D^Z/A]OGN3XQ9.FRN:Q>:ZTSVZMI[BR&R*ZBJ'6* MLW;U[N+<>^\U!B,M3F.LH):/=4=)+32Z-22QR0PD.W-FD:A&5(EH0:8(($K\Y?>S^^5]UCFNUY(]Y=AV7FFU:**2.]B@ MN(4ND896WO(8;6(R1M6.59+`R*ZZJ,C*[ZM_RMZ,QOQH^1':_1.([,VMW%CN MM-S-M^E[(V8(TP&YE^PHJYY8:>+(9:*AR.-EK&HJ^E2KJEINK/M)SY<^Y_MORCS]>RW.Z6OC-97-?&@[V2A)2,LCA1)$YC0R0NCE%+:1NI?\)B]Z;RW+\#>PMN[ M@K*VOVWU]\BMV[?V*]6\CQ8K%979>P=VYC`8XL=$=%3[BW!4UY11Q/DI"?U` M#)?V/N;F;E2\AF8F&&\=4KY`I&Y4?+4Q;[6/7$#^]*V39=L]_P#ES.5_,L884BJ?PPJ/+JKS_A/1_V_T_X4&?\`B?\`Y#?_ M``9_9ON9>N:?6[[[]U[K2!_X4`_]Q"/\@3_Q,'Q[_P#@Q-J>_=>Z![_A4K#W MM6_S@/Y.M!U1D-BXK\24.3C?;D&33 M:C94&GG4T@3RHT?!]U[JS'^X'_"OK_G]_P#*Q_\`/3N[_P"U#[]U[JOS^8A_ M*,_X4F_S0NL=D=3_`"N[,_EKYK;77F_$[$VK6;,R6]]G[AQ^=_N_F=MU--_& MJ/IFHJ'PV0H,TS5%+8)+/34\A-X5]^Z]TV?S,,5E\5_PIQ_D>;>^2E;293;F M&Z)^,N/H:^JGEJ]LY+NB@[+[PIX*ZBJ:V&!*G,5O_=>ZT;/^%K,6P?[C_RVYJP8\=HCNGMF+;I]'\5;8)Q'7+;S`(/E./3< M0P-]5U$C#38EK^Z]UL2?SY?^W.O\PW_Q7#=O_N1C??NO=%P_X2X_]N*/@S_Y M_=>Z6'_``MH_P"R!?BC M_P"+?T__`+YCM'W[KW6X+UE2TU#UMU]14<$5+1T>Q]ITM+30(L<-/34^!H(8 M((8U`6.**)`JJ.`!;W[KW6F7_P`*>#_#?YIO_"?S-T`6ER\7R0B,>1A55JE_ MA?R*^+M7CAY;:BM%4UZW;/?NO=?_3W^/?NO=$E^>/P,Z1 M_F`]+9#J?MO&K19FA6LR/6W9>,HZ>7=O6>Z9H41,OA9I3$:S%5K011Y/&22+ M39&G0*QCFCIZB`,A`(G/V!^\!S MU]WCG>WYNY/NB]E(52]LG8BWO8`:F.0"NF1:L8)P"\+DD:D:2-]1'XG_`/"= M7Y([M^66Z.OOD]1R;)^/'4V:HZC<'96W:I6@[LQ=1IK[G]Y)[9[1[0[5S%[63"^]Q]W@80V4RYVQQVR2;@H-/TF_L8D8BZ[75A#5 M^MY#K7K7873NPMJ]7]7[4P^R-@;)P]-@MK;6P-**3&8C&4H.B*%+O+-/-*[2 MSSRM)45-1(\TSO*[NV45E96FW6D%C8VZQ6D2A5510`#_`%5).2:DDD]<'^9^ M9^8.=.8-VYJYJW::_P"8;Z9I9YY6U/([<23P``HJ(H"(@5$554`+CVJZ(NJK MOYIO\KGKG^9)U=B:"?+P=?=X]=ID9^J^SOL&KJ6&/(".3([,WG10-'59/9N: MGIXWU1-]UC*I144X=6J::J`?/?(MGSI8QH9!#ND-?"EI49XHXXE&^65.17N5 MLLONH?>KYE^[+S7>7$=FVX\B;D4%_8Z]+$I4)'/&3')I(BE MBTA.\/Y,G\R;HK.UV)ROQ=[`['QU/-(E#NGH_&S]O8/-4R,52NH:;9D60W/0 M0S:3IBR.-H:H#EH5N+XP[I[;HF2)J_LS9&3ZBPM,K,`]14YGM"/:6/6&);L=,C.0+*K-8 M%-9<@?=GY2L9;_`''WJV"XC5:Z+*Z3 M<)6]`L=B;AZGAD`#S(&>MRS^3O\`R=,9_+TQ^:[;[:SF#WW\F=\8,;?J:O;Z MU$^T>L-IU$]-75VU]JUM?34E;FLSF:NCA?)Y1X*=2D*4M-&L2SS5F2'MU[]>N^ MN=OIN7N'9>Y-K]F]38G[O'8Z7);DP57+B,UAXLCE:J@H*9\OL?/Y6&(33Q0M M5&$NP"@@V]R>6Y^9^5[FSLX=>XQ.LL0J!5E-&%20!5&<"I`K2O4>_@ZJCAH]R[1V)15^_TA>&;JJ:GEU,#2P1!;*J@98[W$]P8IF?;+S<&2TJ"/\`$K<"WM.TT*%K>*-W6@I( MSDY))H[_`)R?\BS>OR<[*SGRL^(+8&7M#=%-2R=J=/9O)T6VZ;?&8QM%!CJ; M=^R,_D7IL!CMS9"BI88\C1Y&:CI*MXS5BI2H>5)XN]R/:RYWR]EW_EW1]=(! MXL+$*'(%`Z,>T,0`&#$`TU:JU!SM^Y7]_;8_:WEBP]I/>07`Y5M686&XQ(TS M6L;L7:WNHD!E>!&9FADA622,-X)B,81H]6[N+9PQ4M#G-FX?/86HAN.)(ZAHR.0UO<%S\C\XV\ACDY8OBP_AA M=Q_O2!E_GUU:VO[TOW;]XM$O;3WRY62%A4"?O?Y>72M)\JOD)UM%M7)[?V#NG)T6T#W7O;>?96T,;VINO,Y"7.8>DP_ M\+V;D\ED:*F-?_D]'B::C$LY0&3+#E?EVSY6V6TV>S8LJ5+.10N[99R/*IP! M4T4`5-*]?/K[Z^\O,7OU[F;_`.Y',D2PSW15(+=&+):VL0TP6Z,0"VE:M(^E M?$E>232NO2-4;^6WTW_/W^&/\Q'Y6?,"7^5=1Y"+Y]=QY;Z^>Q M_,3Z=_G^?,?^8M\4_FA_PU518R3X(=H87,]48G`]J]>R;?[2PW7/=5/V9MBO MW3)ENU$R^,7',RXG+SXR*DRM5G#BIZ?&QO3XG#TTE?4Y(>Z]U8'_/=_DX MM_-5Z5Z^W!U%O2BZF^8_QIS60W?\>NR*RJR.)Q=<]?)C*W+["W/G,'#/F\%1 M9'*8&@K\9EZ:*HJ<+E*-9(XS%/5*_NO=5@]7?S:?^%&'QWVQ0=$?);^2/OWY M0=R;P!@JOZVY,1M'Y MJ?S0/Y5'RIZ4^;7QYV[\)_D1WELWN3J';&QH=TT^]]OXBEK-J4!ZUW]ELIAL MIN-GQU3NZI)K((I#.M/2-H0,RD^Z]U6;_P`)YJ3^;Q\-*#KW^6-\M/@3%L+X MV=.IW;F<1\J(-Z87,4<9W+NO<'8^,VQ2#;N?SN!W-'GM\;KKFIZN"2&:*CF1 M)J='B=S[KW1'^I?C=_.A_D@?/[^8%O+XB?`O%?.OXY?-KLH;[VSN#$;WQF'G MQ-+C]Z=C[OV'2Y=:7,Q9[;6:VC2=L9/&9>.OQ24&0D1*BDJEB4W]U[I7_P#" MD?H;^P^NNV^O>^MM]E;"ILYOO/9KH:AI-\ M;?R&W=U;[P_\.H=J;YWSF<6DH@1YOX4D@U))K;W7NMG+^6!V[\VNX_C=5YGY MZ?%?%?$3N#:^_JW8VW.M\3N_';T@SW6F!V7L6?!;]GRF+S>>IJ:KS&XZ]U M9%_PYO\`\*7/^]%'7_\`Z4'M7_[9/OW7NO_4W^/?NO=>]^Z]U[W[KW7O?NO= M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[ MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=> M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]7?X]^Z]U[W[KW7O?NO M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= E>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__V3\_ ` end